Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Seer, Inc.NASDAQ: SEER

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin narrows to -617.8%

Operating margin was -617.8% in Q1 FY2026, down 124.8 pp from a year earlier. On a trailing-twelve-month basis it was -496.4%, up 134.5 pp year over year. Over 3 fiscal years it widened by 180.9 pp.

Context

  • Operating margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 1 analysts of -392.7% for the fiscal year ending Dec 2026, up from -486.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-617.8%-187.9 pp QoQ
Last fiscal yearDec 2025
-486.7%+231.0 pp YoY
LTMMar 2026
-496.4%+134.5 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-124.8 pp+84.2 pp+209.0 pp
1 year+231.0 pp+94.0 pp-137.1 pp
3 years+180.9 pp+296.4 pp+115.5 pp
5 years+448.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-486.7%
Year-over-year change
+231.0pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How SEER compares with its peers on the latest reported figures

  • SEER's LTM Mar 2026 operating margin of -496.4% is the 6th highest of the 10 companies compared; the peer median is -345.2%.
  • Its year-over-year change of +134.5 pp is the 3rd highest of 9, against a peer median of -188.7 pp.
  • Over three fiscal years its change of +180.9 pp compares with a peer median of +130.9 pp.
SEER Competitors Peer median
Operating Margin for SEER and competitors
Company Period LTM level YoY 3-year change
NRIXNurix Therapeutics, Inc.LTM Aug 202641.3% +360.6 pp+135.8 pp
FHTXFoghorn Therapeutics Inc.LTM Mar 2026-286.2% +128.2 pp+343.6 pp
CCCCC4 Therapeutics, Inc.LTM Mar 2026-326.6% -33.6 pp+125.9 pp
KYMRKymera Therapeutics, Inc.LTM Jun 2026-333.5% +364.0 pp-547.0 pp
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026-345.2% -343.9 pp—
SEERSeer, Inc.LTM Mar 2026-496.4% +134.5 pp+180.9 pp
MNOVMediciNova, Inc.LTM Mar 2026-2164.8% ——
QSIQuantum-Si incorporatedLTM Mar 2026-5199.8% -1995.4 pp—
STTKShattuck Labs, Inc.LTM Mar 2026-5266.4% -3640.0 pp+10697.2 pp
LYELLyell Immunopharma, Inc.LTM Mar 2026-618909.7% -64222.0 pp-565818.0 pp
PHVSPharvaris N.V.FY2025— ——
MLYSMineralys Therapeutics, Inc.FY2025— ——
ORICORIC Pharmaceuticals, Inc.FY2025— ——
CGEMCullinan Therapeutics, Inc.FY2025— ——
SANASana Biotechnology, Inc.FY2025— ——
PEPGPepGen Inc.FY2025— ——
ANTXAN2 Therapeutics, Inc.FY2025— ——
MOLNMolecular Partners AGFY2025— ——
NKTXNkarta, Inc.FY2025— ——
Peer median (excluding SEER) -345.2%-188.7 pp+130.9 pp

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.39M14.69M15.18M13.95M16.12M
Cost of Revenue6.77M14.3M13.73M7.12M14.22M
Gross Profit(374K)384K1.45M6.83M1.9M
Gross Margin-5.8%2.6%9.5%49.0%11.8%
Research & Development29.12M45.8M47.44M50.59M37.77M
Selling, General & Admin42.2M52.63M58.95M56.57M42.58M
Operating Expenses71.32M98.43M106.39M106.93M80.35M
Depreciation & Amortization3.56M5.9M5.58M6.18M6.1M
EBITDA(67.61M)(87.07M)(80.7M)(80.33M)(67.3M)
EBITDA Margin-1057.3%-592.9%-531.5%-575.9%-417.5%
Operating Income(71.7M)(98.04M)(104.94M)(100.1M)(78.45M)
Operating Margin-1121.3%-667.6%-691.2%-717.7%-486.7%
Interest Income326K4.6M17.76M16.67M11.52M
Interest Expense22K0000
Other Income / Expenses527K5.08M18.67M13.6M5.05M
Income Before Tax(71.17M)(92.97M)(86.28M)(86.5M)(73.4M)
Pre-Tax Margin-1113.1%-633.1%-568.3%-620.2%-455.4%
Income Tax Expense00098K201K
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Net Margin-1113.1%-633.1%-568.3%-620.9%-456.6%
EPS (Basic)(1.13)(1.42)(1.35)(1.39)(1.28)
EPS (Diluted)(1.13)(1.42)(1.35)(1.39)(1.28)
Weighted Avg Shares60.86M62.43M63.85M62.35M57.45M
Weighted Avg Shares (Diluted)60.86M62.43M63.85M62.35M57.45M

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.